Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:16211281rdf:typepubmed:Citationlld:pubmed
pubmed-article:16211281lifeskim:mentionsumls-concept:C0597032lld:lifeskim
pubmed-article:16211281lifeskim:mentionsumls-concept:C1518051lld:lifeskim
pubmed-article:16211281lifeskim:mentionsumls-concept:C0016360lld:lifeskim
pubmed-article:16211281lifeskim:mentionsumls-concept:C0312418lld:lifeskim
pubmed-article:16211281lifeskim:mentionsumls-concept:C0441767lld:lifeskim
pubmed-article:16211281lifeskim:mentionsumls-concept:C1527249lld:lifeskim
pubmed-article:16211281lifeskim:mentionsumls-concept:C0034897lld:lifeskim
pubmed-article:16211281lifeskim:mentionsumls-concept:C1446468lld:lifeskim
pubmed-article:16211281lifeskim:mentionsumls-concept:C0036667lld:lifeskim
pubmed-article:16211281lifeskim:mentionsumls-concept:C0205262lld:lifeskim
pubmed-article:16211281pubmed:issue5lld:pubmed
pubmed-article:16211281pubmed:dateCreated2005-10-7lld:pubmed
pubmed-article:16211281pubmed:abstractTextIn 103 patients without occult neoplastic cells (ONCs) in the lymph node sinuses, the 5-year relapse-free survival (RFS) rate and overall survival (OS) rate were 90.2% and 91.8%, respectively. In 21 patients with ONCs, the 5-year RFS and OS rates were 34.9% and 62.3%, respectively. There were marked differences of survival between the two groups (p=0.0000 and p=0.0003). In the primary tumors of the 21 ONC-positive patients, high and low TS levels were found in 46.2% (6/13) and 53.8% (7/13) of the recurrence group (n=13), respectively. High and low DPD levels were found in 23.1% (3/13) and 76.9% (10/13), respectively. In the non-recurrence group (n=8), high and low TS or DPD levels were found in 75.0% (6/8) and 25.0% (2/8) versus 12.5% (1/8) and 87.5% (7/8), respectively. The percentage of patients with high TS and low DPD levels was 23.1% (3/13) in the recurrence group and 62.5% (5/8) in the non-recurrence group (p=0.07). These results suggest that the presence of ONCs had a clear association with the 5-year RFS and OS rates. The recurrence group of ONC-positive patients with stage II/Dukes' B colorectal cancer was unlikely to be highly responsive to 5-FU-based treatment, thus requiring multi-combination chemotherapy using CPT-11 and/or L-OHP.lld:pubmed
pubmed-article:16211281pubmed:languageenglld:pubmed
pubmed-article:16211281pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16211281pubmed:citationSubsetIMlld:pubmed
pubmed-article:16211281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16211281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16211281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16211281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16211281pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:16211281pubmed:statusMEDLINElld:pubmed
pubmed-article:16211281pubmed:monthNovlld:pubmed
pubmed-article:16211281pubmed:issn1021-335Xlld:pubmed
pubmed-article:16211281pubmed:authorpubmed-author:MukaiMasayaMlld:pubmed
pubmed-article:16211281pubmed:authorpubmed-author:MakuuchiHiroy...lld:pubmed
pubmed-article:16211281pubmed:authorpubmed-author:KomatsuNobuka...lld:pubmed
pubmed-article:16211281pubmed:authorpubmed-author:NakasakiHisao...lld:pubmed
pubmed-article:16211281pubmed:authorpubmed-author:SatoShinkichi...lld:pubmed
pubmed-article:16211281pubmed:authorpubmed-author:NinomiyaHirom...lld:pubmed
pubmed-article:16211281pubmed:authorpubmed-author:WakuiKanakoKlld:pubmed
pubmed-article:16211281pubmed:authorpubmed-author:TsuchiyaKazut...lld:pubmed
pubmed-article:16211281pubmed:issnTypePrintlld:pubmed
pubmed-article:16211281pubmed:volume14lld:pubmed
pubmed-article:16211281pubmed:ownerNLMlld:pubmed
pubmed-article:16211281pubmed:authorsCompleteYlld:pubmed
pubmed-article:16211281pubmed:pagination1171-6lld:pubmed
pubmed-article:16211281pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:meshHeadingpubmed-meshheading:16211281...lld:pubmed
pubmed-article:16211281pubmed:year2005lld:pubmed
pubmed-article:16211281pubmed:articleTitleRecurrence and 5-FU sensitivity of stage II/Dukes' B colorectal cancer with occult neoplastic cells in lymph node sinuses.lld:pubmed
pubmed-article:16211281pubmed:affiliationDepartment of Surgery, Tokai University Hachioji Hospital, Ishikawa-cho 1838, Hachioji, Tokyo 192-0032, Japan. mukai.masaya@hachioji-hosp.tokai.ac.jplld:pubmed
pubmed-article:16211281pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:16211281pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed